These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25209010)

  • 1. Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A.
    Kouris A; Agiasofitou E; Gregoriou S; Sofouri E; Kontochristopoulos G; Panagopoulos G
    Int J Dermatol; 2014 Nov; 53(11):e544-7. PubMed ID: 25209010
    [No Abstract]   [Full Text] [Related]  

  • 2. Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis.
    Chiarello D; Piombo M; Corbetto M; Di Pino G; Assenza G; Capone F; Di Lazzaro V
    Muscle Nerve; 2014 Sep; 50(3):456-7. PubMed ID: 24890202
    [No Abstract]   [Full Text] [Related]  

  • 3. Muscle weakness in treatment of palmar hyperhidrosis with botulinum toxin type a: can it be prevented?
    Kouris A; Vavouli C; Markantoni V; Kontochristopoulos G
    J Drugs Dermatol; 2014 Nov; 13(11):1315-6. PubMed ID: 25607695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of palmar hyperhidrosis with botulinum neurotoxin a.
    Mannava S; Mannava KA; Nazir OF; Plate JF; Smith BP; Koman LA; Tuohy CJ
    J Hand Surg Am; 2013 Feb; 38(2):398-400. PubMed ID: 23267759
    [No Abstract]   [Full Text] [Related]  

  • 5. Writer's block: "texting" impairment as a complication of botulinum toxin type A therapy for palmar hyperhidrosis.
    Lehman JS
    Arch Dermatol; 2011 Jun; 147(6):752. PubMed ID: 21690551
    [No Abstract]   [Full Text] [Related]  

  • 6. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of hyperhidrosis with botulinum toxin.
    Doft MA; Hardy KL; Ascherman JA
    Aesthet Surg J; 2012 Feb; 32(2):238-44. PubMed ID: 22328694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myaesthenia gravis exacerbation caused by axillary injection of botulinum toxin A for treatment of hyperhidrosis.
    El-Heis S; Burke G; Gibb W; Ardern-Jones MR
    Clin Exp Dermatol; 2017 Apr; 42(3):357-359. PubMed ID: 28111784
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study.
    Muller F; Cugy E; Ducerf C; Delleci C; Guehl D; Joseph PA; Burbaud P; Dehail P
    Clin Rehabil; 2012 Feb; 26(2):174-9. PubMed ID: 21937525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following botulinum toxin type A treatment in children with cerebral palsy.
    Langdon K; Blair E; Davidson SA; Valentine J
    Dev Med Child Neurol; 2010 Oct; 52(10):972-3; author reply 974. PubMed ID: 20561011
    [No Abstract]   [Full Text] [Related]  

  • 11. Complications and side-effects of botulinum toxin A.
    Schaffner R; Kreyden OP
    Curr Probl Dermatol; 2002; 30():141-8. PubMed ID: 12471708
    [No Abstract]   [Full Text] [Related]  

  • 12. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis.
    Rosell K; Hymnelius K; Swartling C
    Acta Derm Venereol; 2013 May; 93(3):335-9. PubMed ID: 23053164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contralateral weakness following botulinum toxin for poststroke spasticity.
    Thomas AM; Simpson DM
    Muscle Nerve; 2012 Sep; 46(3):443-8. PubMed ID: 22907238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.
    Baumann LS; Halem ML
    Arch Dermatol; 2003 Feb; 139(2):226-7. PubMed ID: 12588237
    [No Abstract]   [Full Text] [Related]  

  • 15. The place of botulinum toxin type A in the treatment of focal hyperhidrosis.
    Lowe N; Campanati A; Bodokh I; Cliff S; Jaen P; Kreyden O; Naumann M; Offidani A; Vadoud J; Hamm H
    Br J Dermatol; 2004 Dec; 151(6):1115-22. PubMed ID: 15606505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin for focal hyperhidrosis of the face.
    George SM; Atkinson LR; Farrant PB; Shergill BS
    Br J Dermatol; 2014 Jan; 170(1):211-3. PubMed ID: 23909999
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic effect of local and small-dose botulinum toxin injection to unmask subclinical myasthenia gravis.
    Iwase T; Iwase C
    Graefes Arch Clin Exp Ophthalmol; 2006 Mar; 244(3):415-6. PubMed ID: 16175373
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of compensatory hyperhidrosis with botulinum toxin type A.
    Belin EE; Polo J
    Cutis; 2003 Jan; 71(1):68-70. PubMed ID: 12553633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Botulinum toxin in the treatment of focal hyperhidrosis].
    Schnider P; Moraru E; Kittler H; Voller B; Kranz G; Auff E
    Wien Klin Wochenschr; 2001; 113 Suppl 4():36-41. PubMed ID: 15506051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to save botulinum toxin A in the treatment of focal axillary hyperhidrosis.
    Bechara FG; Sand M; Hoffmann K
    Dermatology; 2006; 213(4):356. PubMed ID: 17135747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.